Volume 15 - Issue 9 - September 2002
Wound Care Q&A »
The array of wound care products can be quite astounding. Choosing the right product(s) for your patient can be difficult. With this in mind, our panelists, strongly emphasizing case-by-case management, share their experiences, success stories and caveats with certain wound care products. Read on for what five expert panelists had to say about treating neuropathic ulcers, when to use growth factors and the role of wet-to-dry dressings.
Q: What wound care products do you use on the diabetic neuropathic ulcer?
A: All of the panelists agree that appropriate product selection is done on
Dermatoses of the lower extremities are fairly common.1 These conditions include infectious, inflammatory, vascular, neoplastic and traumatic dermatoses. Many dermatologic conditions (i.e. psoriasis, lichen planus) that exhibit the potential for widespread distribution can be prone to occur on the legs, ankles or feet in some patients. Other disorders characteristically involve the lower extremities. For example, dyshidrotic eczema and pitted keratolysis are examples of dermatoses that involve the plantar surface of the foot.
High contact. High intensity. It’s no surprise that many injuries occur on the football field. An injury may occur as an athlete is blocking an opposing player or as he is being tackled by another player. Other injuries may occur when players either sprint downfield, make sharp cuts to avoid being tackled, or make other movements that involve much rotation in order to catch or deflect the football. Playing surfaces can also lead to injuries (see “Artificial Turf Vs. Natural Grass: Which Is Better?” on page 48).
Certainly, the first metatarsal phalangeal joint is one of the most injured
Onychomycosis is a common nail infection, which is often chronic, difficult to eradicate and tends to recur.1 Current therapeutic approaches include mechanical or chemical avulsion, topical therapy, oral therapy or a combination of one or more of these treatment modalities. Treatment of onychomycosis has improved greatly with the addition of broad-spectrum oral antifungal agents and topical nail lacquers. However, even with the therapeutic advances, onychomycosis continues to increase in prevalence, treatment is not always successful, and relapse and reinfection may occur even after
All medical practices are essentially small enterprises, not very different from any of the Fortune 500 companies. Practices generate revenue by providing services or selling products. They also have expenses for staff, rent, equipment and insurance. There are also elements of marketing, finance, human resources, etc. Like all companies, podiatric practices are challenged by inefficiency and the desire to continue improving on their profit margins.
When the typical private practitioner hears phrases such as “Quality Improvement,” “Total Quality Management (TQM)” or “Process Enhancem
Statistics from the American Diabetes Association (ADA) reveal there were 86,000 amputations due to complications from diabetes mellitus in 2000. The ADA also points out that 50 to 70 percent of these patients will develop peripheral neuropathy sometime in the course of their disease.1
The most widely believed paradigm in mainstream medicine today is that loss of sensation in diabetic peripheral neuropathy is irreversible and the only treatment available is the achievement of euglycemic control and the ancillary use of medicines such as Elavil and Neurontin.2 Sadly, this
- « Previous
- | Page 1 of 3 |
- Next »